Bildkälla: Stockfoto

Optomed Q1: Solid results - Redeye

Redeye maintains Optomed's valuation at EUR 13 per share after today's solid Q1 report. In the months ahead, we expect accelerated camera and software revenue growth.

Redeye maintains Optomed's valuation at EUR 13 per share after today's solid Q1 report. In the months ahead, we expect accelerated camera and software revenue growth.
Börsvärldens nyhetsbrev
ANNONSER